CA2463649A1 - Mimetiques de rankl et utilisations de ceux-ci - Google Patents

Mimetiques de rankl et utilisations de ceux-ci Download PDF

Info

Publication number
CA2463649A1
CA2463649A1 CA002463649A CA2463649A CA2463649A1 CA 2463649 A1 CA2463649 A1 CA 2463649A1 CA 002463649 A CA002463649 A CA 002463649A CA 2463649 A CA2463649 A CA 2463649A CA 2463649 A1 CA2463649 A1 CA 2463649A1
Authority
CA
Canada
Prior art keywords
rankl
sequence
seq
mimic
tnf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002463649A
Other languages
English (en)
Inventor
Jonathan Lam
F. Patrick Ross
Steven L. Teitelbaum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Barnes Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Barnes Hospital filed Critical Barnes Hospital
Publication of CA2463649A1 publication Critical patent/CA2463649A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/42—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving phosphatase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des protéines d'origine non naturelle qui se lient à RANK, ainsi que des polynucléotides codant pour celles-ci. Les protéines de cette invention peuvent être utilisées pour améliorer la formation osseuse soit en empêchant la résorption osseuse soit en induisant l'ostéogenèse.
CA002463649A 2001-10-15 2002-10-15 Mimetiques de rankl et utilisations de ceux-ci Abandoned CA2463649A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32939301P 2001-10-15 2001-10-15
US60/329,393 2001-10-15
PCT/US2002/033022 WO2003033663A2 (fr) 2001-10-15 2002-10-15 Mimetiques de rankl et utilisations de ceux-ci

Publications (1)

Publication Number Publication Date
CA2463649A1 true CA2463649A1 (fr) 2003-04-24

Family

ID=23285176

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002463649A Abandoned CA2463649A1 (fr) 2001-10-15 2002-10-15 Mimetiques de rankl et utilisations de ceux-ci

Country Status (5)

Country Link
EP (1) EP1444341A2 (fr)
CA (1) CA2463649A1 (fr)
IL (1) IL161387A0 (fr)
MX (1) MXPA04003528A (fr)
WO (1) WO2003033663A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005530482A (ja) 2002-01-04 2005-10-13 ゼンコー・インコーポレイテッド ドミナントネガティブタンパク質およびそれらの用法
US7381792B2 (en) 2002-01-04 2008-06-03 Xencor, Inc. Variants of RANKL protein
WO2006024096A1 (fr) * 2004-08-31 2006-03-09 Chemgenex Pharmaceuticals Limited Procédé servant à moduler l'ostéoclastogénèse
EP1899453B1 (fr) 2005-06-07 2013-12-18 Ocean Nutrition Canada Limited Micro-organismes eucaryotes pour produire des lipides et des antioxydants
EP1854458A1 (fr) * 2006-05-08 2007-11-14 IMBA-Institut für Molekulare Biotechnologie GmbH Utilisation d'un composé avec activité RANKL
WO2013024040A2 (fr) * 2011-08-12 2013-02-21 B.S.R.C. Alexander Fleming Inhibiteurs de trimérisation de la superfamille des tnf
CN108064231A (zh) * 2015-05-20 2018-05-22 国立大学法人大阪大学 具有炎性细胞因子分泌抑制活性的寡肽

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69740107D1 (de) * 1996-12-23 2011-03-10 Immunex Corp Rezeptor aktivator von nf-kappa b, rezeptor is mitglied der tnf rezeptor superfamilie

Also Published As

Publication number Publication date
WO2003033663A3 (fr) 2003-10-23
IL161387A0 (en) 2004-09-27
WO2003033663A2 (fr) 2003-04-24
WO2003033663A8 (fr) 2003-12-11
EP1444341A2 (fr) 2004-08-11
MXPA04003528A (es) 2004-07-23

Similar Documents

Publication Publication Date Title
EP1771557B1 (fr) Propeptides GDF3 et méthodes associées
US8334101B2 (en) Intracellular DNA receptor
KR102051159B1 (ko) 단백질 간의 상호작용의 판정 방법
JP6509867B2 (ja) 疾患及び障害を治療するためにインターロイキン−１０を使用する方法
US8268635B2 (en) Methods of identifying agents that selectively activate p38 and/or NKkB signaling
Koschut et al. Live cell imaging shows hepatocyte growth factor-induced Met dimerization
JP2019500414A (ja) 熱安定性ｆｇｆ２ポリペプチド及びその使用
Qiu et al. A missense mutation sheds light on a novel structure–function relationship of RANKL
CA2463649A1 (fr) Mimetiques de rankl et utilisations de ceux-ci
SAGHIR et al. Modifications of eukaryotic initiation factor 4F (eIF4F) in adult cardiocytes by adenoviral gene transfer: differential effects on eIF4F activity and total protein synthesis rates
US20050119174A1 (en) Novel blood sugar controller and method of screening the same
CN105535932B (zh) 三个多肽片段在制备抗纤维化药物中的医药用途
US20030100068A1 (en) RANKL mimics and uses thereof
Smith et al. Identification of regions of arrestin that bind to rhodopsin
WO2000006087A2 (fr) Proteine-2 (ucp2) dissociante: compositions et procedes d'utilisation
EP1504124A1 (fr) Proteines 1 et 2 associees aux recepteurs des lipoproteines de faible densite (ldl) et traitement de pathologies osseuses ou cartilagineuses
AU2002343524A1 (en) RANKL mimics and uses thereof
Wang et al. TRAF3 negatively regulates calcineurin‐NFAT pathway by targeting calcineurin B subunit for degradation
US20030109444A1 (en) Bone anti-resorptive compounds
Silva et al. A previously-unrecognized motif of transcription factor RYBP, hotspot of cancer-related mutations, is essential for the integrity of Polycomb repressive complex 1
WO2006001770A1 (fr) Methode permettant d'identifier des modulateurs des recepteurs de classe i de la cytokine
WO2024077251A2 (fr) Mimétiques de l'interleukine-21
Edirisinghe et al. Check for updates Chapter 10 Overexpression and Purification of Mitogenic and Metabolic Fibroblast Growth Factors Phuc Phan, Shivakumar Sonnaila, Gaetane Ternier
US20040023311A1 (en) Modulation of angiogenesis through targeting of cysteine oxygenase activity
KR20190005240A (ko) Tgf-베타 슈퍼패밀리의 ab6 패밀리 디자이너 리간드를 포함하는 골 및 연골 질환 치료용 조성물 및 그의 이용

Legal Events

Date Code Title Description
FZDE Discontinued